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Background
Decision-makers utilize the results of economic analysis in a wide
range of settings that include governmental agencies, managed
care, and other health-care payers [1,2]. A cornerstone of such
analysis is the quality-adjusted life-year (QALY), which is formed
by the arithmetic product of quantity and quality of life. The
expansion in use of economic evaluation by health agencies has
mirrored the growing recognition of the usefulness of health-
related quality of life (HrQoL) as an important indicator of
outcome of disease treatment among clinicians and patients
[3–7]. This information has a dual use in that it informs both
clinicians and health economists in the evaluation of treatment
options. The use of the QALY as a health outcome measure for
groups of patients is fairly clear for payers, managed care, and
governmental organizations who seek to make decisions that
maximize the value of health-care spending in terms of health
outcomes achieved through the most efﬁcient use of limited
resources. Nevertheless, the importance and need to bring
QALYs into the wider decision-making process of clinicians and
patients is more controversial.
For the purposes of this article, it is assumed that economic
evaluation of health-care interventions by national reimburse-
ment or other health-care decision-making bodies is largely a
given, although there clearly are health-care jurisdictions in
which this is not the case. Nevertheless, in a global marketplace,
the requirements of dominant health-care jurisdictions are likely
to inﬂuence the behaviors of other stakeholders across the world
community. Hence, the inﬂuential role of cost-utility analysis
(CUA) as part of an information toolkit for high-level decision-
making is unlikely to be radically altered in the next 5 to 10
years. Central to CUA is the need for an outcome measure that
combines the effects of health interventions on mortality and
morbidity into a single index—the QALY. Critical to the compu-
tation of QALYs is the assessment of the impact of morbidity,
represented through the measurement of HrQoL from data gath-
ered in clinical trials and observational studies. Although these
same data are applied in the economic evaluation of new health
technologies, they may also be used in other non-economic appli-
cations, for example, in monitoring health status in individual
patients, or in measuring population health or the impact of
therapies in clinical studies.
Different health jurisdictions permit or require different
forms of HrQoL measurement in the economic evaluation of
health technologies. Some stipulate that the weights used to value
HrQoL states are social preferences that reﬂect the views of the
general population. Others are open to the use of values derived
from patients or others directly affected by the health technology.
The question as to whose values do (or should) count is a matter
for local arbitration within the decision-making framework of
speciﬁc societies and their individual health-care systems. Ulti-
mately, it is a political choice. It is not (and should not be)
determined by health economists or other single stakeholder
groups. For the purposes of this article, it is sufﬁcient to note that
the quality-adjustment factor used in computing QALYs can
emanate from several sources and may or may not represent the
views of the patient or those who care for them.
It is worth brieﬂy reﬂecting on both “decision-maker” as an
attribute of an individual or set of individuals and “decision-
making” as an activity undertaken by members of that set. High-
level policy that shapes the development of health-care programs
is clearly distinct from the day-to-day delivery of care to patients.
Decision-making activity in support of the former is more likely
to make use of economic evaluation than is the case in the latter.
Policy formation is informed to some extent by aggregated mea-
sures of costs and beneﬁts. Individual clinicians may contribute
to those data but more often are faced with decisions that are
made in relative ignorance of the wider societal-level picture. A
decision by a clinician to admit a patient to hospital for treat-
ment, or to provide innovative therapy or embark on diagnostic
investigations is likely to be taken with minimal reference to the
evidence of any economic evaluation (should it exist). Con-
versely, health programs are more likely to be formulated with
regard for evidence of effectiveness and cost-effectiveness of such
interventions when applied to population subgroups, occasion-
ally to whole populations.
This article addresses a number of related issues that stem
from a more widely drawn interpretation of the QALY in which
its status as a composite measure of health beneﬁt is recognized,
but where its role is not wholly contained within or limited to
a cost-effectiveness framework. Under what circumstances is
QALY-based information of value to decision-makers such as
clinicians and other staff with direct responsibility for patient
care? Is the QALY in its present format useful for the comparison
of health outcomes within a given therapeutic area? How might
the value to clinicians and patients of QALY-based information
and its application in low-level decision-making be enhanced?
And ﬁnally, what obstacles need to be overcome in extending the
uses and usefulness of the QALY to noneconomist health-care
decision-makers?
QALYs and Decision-Making
Taking the QALY as a given part of economic evaluation and a
fundamental component of CUA, it is an open question as to
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whether the QALY is useful to health-care decision-makers
outside that reference space. The question might be more widely
posed in respect of the general role of economic evaluation in
health-care decision-making. Is there a universal beneﬁt that
derives from its use across all levels of decision-making or is that
beneﬁt restricted to speciﬁc applications? Here, it is more useful
to see the QALY simply as a summary measure of health beneﬁt
intended in the ﬁrst instance for use in one speciﬁc application
but potentially of value in other settings. To address its wider
usefulness requires the consideration of 1) the type of decisions
that are made by those charged with the responsibility of plan-
ning, managing, allocating resources, and delivering health care;
2) the organizational level at which such decisions are made; and
3) the role of individuals and groups of individuals within that
organization. Figure 1 displays how the application of QALYs
might (from a theoretical standpoint) extend across different
types of decision-makers. The columns list decision-making seg-
ments in a health-care delivery system, and the rows represent the
type of measurement/focus of interest.
This matrix helps to identify a set of potential users within
sectors within a health-care system or organization and the dif-
ferent levels at which QALY-based information might be used for
different forms of observation and measurement. Cells that are
shaded black exemplify situations in which a QALY is currently
unlikely to be of relevance—for example, in government-level
decisions made with respect to individual patients. Cells that are
left unshaded indicate situations in which QALY-based informa-
tion might have potential for practical decision-making, for
example, those made by provider units in respect of individual
patients. Cells that are partially shaded indicate a mixed assess-
ment of QALY potential. Entries for some cells only exist from a
theoretical point of view because no practical use for QALYs can
be envisaged at the present time. For example, in informing
decisions about individual patients, it is relevant to consider
patient-speciﬁc data on quality and quantity of life rather than
QALYs based on aggregated data that incorporate a societal
perspective on the value of any health beneﬁts. Further study
would be required to test the comprehensiveness of the decision
set described in Figure 1 and it is included here only by way of
illustration.
We note that the literature regarding patient involvement
in health treatment decision-making is expanding with the
increased sophistication and access to information about health-
care alternatives [8,9]. Research regarding improved effectiveness
of the patients’ participation in their own health decisions
through the use of HrQoL and quantity of life measures have
involved treatments for cancer [3,10–13], hepatitis C [14], heart
failure [15], dialysis [16], Parkinson’s disease [17], and sickle cell
anemia [18]. The application and relevance of HrQoL and QALY
measures to clinicians is expanding and it is possible to ﬁnd
examples that report the use of QALYs in a range of conditions
such as heart failure [19], diabetes [20], and oncology [4–7]. The
use of cost-effectiveness analyses that incorporate QALY out-
comes to supplement formulary decisions is also increasing in
managed care pharmacy [2–21].
Two characteristics of the QALY are important when it comes
to identifying potential uses and users. First, the QALY is a
generic measure which means that for some clinicians, it will
be seen as lacking the speciﬁcity that is required in daily prac-
tice. Second, the weighting system used to compute the
quantity ¥ quality product is most often calibrated in terms of
social preferences—not those of the patient or other beneﬁciaries
of treatment. Hence, the criticism that the value attached to
quality of life may be determined by wholly disinterested and
ill-informed third parties. This represents a more signiﬁcant chal-
lenge to those who advocate for the wider use of the QALY as a
measure of health outcome.
The QALY’s constituent elements (HrQoL and survival) sepa-
rately provide information in measuring outcomes. For example,
if a choice is to be made between two therapies in oncology, if
one has a 60% chance of survival to 5 years and the second
has an 80% survival rate, and if survival were the only choice
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Figure 1 Users and uses of health outcomes data.
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criterion, then the latter would be preferred to the former as it
maintains the patient’s existence for longer. When viewed solely
in terms of quantity of life (survival), one therapy dominates the
other. Nevertheless, such a comparison wholly discounts any
quality of life differential. By opting to use QALY-based infor-
mation, the HrQoL component would be given a status that is
absent when only survival is used to differentiate treatment
options. The relevance of such considerations in patient-centered
decision-making is more common in therapeutic areas such as
oncology where trade-offs between life expectancy and the
quality of the time that remains are particularly salient. It is for
this reason that standardized measures of HrQoL are more
numerous and have been in widespread use for longer.
For the clinical decision-maker working within a given thera-
peutic area, there sometimes can be little to encourage them to
use the QALY as a measure of health beneﬁt. Where there is no
differential effect on survival and a decision is to be made
between (say) two alternative surgical procedures, for example,
in ﬁxing a fractured femur, any marginal HrQoL outcomes
would be the principal driver in accounting for any QALY dif-
ferences. What then would be the practical value for the ortho-
pedic surgeon who is invited to see the wider potential use of
QALY-based information in setting priorities outside of his spe-
cialist area? What is to be gained for him or his patients from this
more generalized measurement of outcomes?
Despite all this, there does seem to be some scope for a wider
management role for the QALY quite apart from its primary
application within cost-effectiveness analysis. For example, one
recently reported an application that demonstrated the use of
QALYs in the valuation of quality improvement in diabetes man-
agement [22]. The Diabetes Risk Factor Control (a disease man-
agement program) [22] used a QALY-based metric to examine
performance in terms of delivering improved outcomes to
patients with diabetes by adopting appropriate monitoring and
treating strategies for those patients. Historically, most diabetes-
related quality measures have focused on multiple process
measures that have not been empirically linked to improved
outcomes, or on single risk factor levels typically represented as
percents of patients in “control.” As such, not only does typical
monitoring and measurement not enable decision-makers to con-
sider the value associated with a decision to allocate resources to
the care of patients with diabetes compared to allocations in
other clinical areas, but it also does little to inform the allocation
of resources across multiple diabetes care management options.
A summary measure based on a standard metric has the potential
to greatly improve decision-making. Figure 2 exempliﬁes the use
of expected mean change in QALYs gained as an index of per-
formance in 16 Kaiser Permanente Medical Centers.
Although providers and patients are interested in separately
incorporating information on HrQoL and quantity of life in
treatment decision-making, improving the relevance of the
QALY as a composite measure to these groups of users involves
promoting its interpretability. The QALY was developed to
inform top-down decision-making processes through the
medium of CUA. Nevertheless, a different practical and theoreti-
cal underpinning is needed if it is to have relevance to patients
and clinicians. Some attempt is necessary to bridge that gap and
adapt QALY measures to render them more applicable in the
clinical setting. This could involve methods that place HrQoL
measures in the hands of the patient and clinician at the point of
decision-making, thereby generating QALY results that are rel-
evant to the clinical situation.
The apparent lack of consensus among HrQoL instrument
developers, methodologists, and health economist weakens the
case for accepting the QALY as a standard metric. Criticism is
played down or circumvented. So for example, although it is
generally acknowledged that different utility elicitation methods
yield different quantitative estimates, there is no agreement on
which of these variants constitutes the preferred method—or
indeed whether any such choice exists at all. Observations of this
sort tend to be dismissed but in so doing entirely miss the point
that the existence of a standard method would be consistent with
a mature QALY technology. A similar argument can be made
regarding the selection of a reference source for the values them-
selves. The preference for social values over patient (or caregiver)
values is contingent on the belief system of the QALY user. For
non-economists, the discounting of patient values is hard to
understand or tolerate.
Moving the QALY forward
There is a need to develop evidence of the importance of the
independent usefulness of the disaggregated QALY components
and to decouple what are essentially technical issues around the
valuation of health status. The mechanics for collecting patient-
based HrQoL assessments have been presaged in the UK
National Health Service with the requirement from 2009 for pre
and postsurgery measurement of health status in selected proce-
dures [23]. Embedding such data within national health infor-
mation systems should make for an easier interpretation of
QALY-based information. Assimilating HrQoL into routine clini-
cal practice will assist the longer-term development of other uses
for those same data.
The routine use of HrQoL in operational and clinical con-
texts will itself help move the QALY forward. Including it as part
of the process of delivering care would change the way people
regard decisions that are based on it. But there needs to be some
sort of recommendation about which HrQoL system to use
because continuing debate about the choice of system creates a
signiﬁcant problem, confusing the process of understanding and
undermining attempts to show how HrQoL data might be cre-
atively exploited. Going back to decision-makers and asking
them what might be useful and in what context is an important
ﬁrst step in achieving real change. Getting decision-makers to
accept this tool means ensuring that they have some experience
with it. This is an educational prerequisite and starts with getting
an understanding of how HrQoL can be used in patient-level
decision-making. In moving the QALY forward, it may be helpful
to consider approaches such as the transtheoretical model (TTM)
Figure 2 Clinical decision-making in diabetes. QALY, quality-adjusted life-year.
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of change, developed by Prokaska [24,25]. The TTM model has
been successfully applied in studies of patient decision-making
[26]. The TTM model proposes that we think of decision-makers
as being in different stages in their potential ability and interest to
use QALYs. For example, patients are probably unaware that
QALYs exist and although providers may be aware of them, they
may be skeptical or perplexed by them. Different strategies and
educational efforts are needed based on the TTM stage in which
individual currently resides.
Conclusions
There are merits in the use of the QALY within the mainstream
of decision-making concerned with questions of resource alloca-
tion within patient populations, but the boundaries of practical
usefulness are only slowly evolving. For a more generalized adop-
tion of the QALY as a component in decision-making beyond its
traditional economic evaluation hinterland, several things must
happen. To go beyond cost-effectiveness applications that explic-
itly legitimize the QALY requires a concerted effort to rigorously
evaluate the use of QALYs in a variety of decision-making situ-
ations. Such evaluations would include those that consider both
the perceived quality of decision-making process and as well as
their ﬁnal results. We need to improve our understanding of the
extent to which decision-makers would utilize information based
on QALYs. That is an issue that seems ripe for investigation. The
paucity of evidence that bears on this issue suggests that this is an
unknown area. To make progress here, we have to do more than
assert that there is a ready audience for this kind of information.
Investigating the issue and identifying the value to real-world
clinicians and patients is the proper way to proceed. ISPOR
should take a leadership role in this educational process, so that
good practice and guidance in delivering the technology for
applying QALYs would follow.
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